May 28, 2025
Technology
Antibody drug conjugates (ADCs) have emerged as an exciting modality in cancer treatment, though first-generation approaches have shown limitations. Our approach leverages a next wave ADC platform technology engineered for a high therapeutic index and stability, coupled with best-in-class tumor targeting approaches. Combined, these create a powerful foundation for oncology asset development.
Pipeline
Our ADC portfolio consists of three assets designed to target proteins that are clinically validated and broadly expressed across tumor types with significant patient needs, with an initial focus on lung and gynecological cancers.
